文献速递胸部肿瘤

一线奥希替尼治疗初治非小细胞肺癌罕见EGFR突变:UNICORN 2期非随机临床试验

First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项多中心、开放标签、单组2期非随机临床试验纳入40例携带罕见EGFR突变(排除外显子20插入)的初治转移性非小细胞肺癌患者,口服奥希替尼80 mg每日一次。客观缓解率为55.0%(90% CI 40.9%-68.5%),疾病控制率90.0%,中位无进展生存期9.4个月,3或4级不良事件27.5%,间质性肺病12.5%,无治疗相关死亡。

要点

  • 初治罕见EGFR突变转移性非小细胞肺癌中,奥希替尼客观缓解率55.0%、疾病控制率90.0%。
  • 中位无进展生存期9.4个月、中位治疗失败时间9.5个月,中位总生存期未达到。
  • 3或4级不良事件发生率27.5%,间质性肺病12.5%,所有不良事件可控,无治疗相关死亡。

核心结论

  • 奥希替尼在携带除外显子20插入以外的罕见EGFR突变的初治转移性非小细胞肺癌患者中显示出临床活性,毒性可控。
  • 结果支持将奥希替尼作为该患者人群的一种治疗选择。

研究设计与样本

  • 多中心、开放标签、单组、2期非随机临床试验,2020年4月10日至2022年5月31日入组,末例患者入组后随访6个月。
  • 研究入组42例罕见EGFR突变患者,其中40例符合纳入标准,按意向治疗原则分析。
  • 干预为奥希替尼80 mg每日一次口服。
  • 主要终点为客观缓解率,次要终点包括疾病控制率、无进展生存期、治疗失败时间、总生存期、缓解持续时间和安全性。

主要发现

  • 40例符合纳入标准患者中,男性22例(55.0%),中位年龄72岁(范围39.0-88.0岁)。
  • 最常见突变为G719X(20例[50.0%])、S768I(10例[25.0%])和L861Q(8例[20.0%])。
  • 客观缓解率为55.0%(90% CI 40.9%-68.5%),疾病控制率为90.0%(95% CI 76.3%-97.2%)。
  • 中位随访12.7个月(范围2.7-30.7个月)时,中位无进展生存期9.4个月(95% CI 3.7-15.2个月),中位治疗失败时间9.5个月(95% CI 5.6-30.3个月)。
  • 中位总生存期未达到(95% CI 19.3个月至未达到),中位缓解持续时间22.7个月(95% CI 9.5个月至未达到)。

关键数值与推荐

  • 单发罕见EGFR突变患者客观缓解率45.5%(90% CI 26.9%-65.3%),复合罕见EGFR突变患者66.7%(90% CI 43.7%-83.7%)。
  • 单发罕见EGFR突变患者中位无进展生存期5.4个月(95% CI 3.6-22.7个月),复合罕见EGFR突变患者9.8个月(95% CI 5.1个月至未达到)。
  • 单发罕见EGFR突变患者中位总生存期23.0个月(95% CI 12.3个月至未达到),复合罕见EGFR突变患者未达到。
  • 单发罕见EGFR突变患者中位缓解持续时间22.7个月(95% CI 3.6-22.7个月),复合罕见EGFR突变患者未达到(95% CI 5.7个月至未达到)。
  • 11例患者(27.5%)报告3或4级不良事件,5例患者(12.5%)发生间质性肺病。

临床怎么用

  • 作者认为,奥希替尼可作为携带除外显子20插入以外的罕见EGFR突变的初治转移性非小细胞肺癌患者的一种治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Non-small cell lung cancer (NSCLC) with uncommon EGFR mutations is a rare subgroup, composing 14% of all EGFR mutations. OBJECTIVE: To determine the usefulness of osimertinib in previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion mutations. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, single-group, phase 2 nonrandomized clinical trial enrolled patients from April 10, 2020, to May 31, 2022, with a follow-up of 6 months from the date the last patient was enrolled. The study enrolled 42 patients with uncommon EGFR mutations, of whom 40 were eligible. INTERVENTION: Osimertinib, 80 mg once daily, was administered orally to patients. MAIN OUTCOMES AND MEASURES: The primary end point was the overall response rate (ORR). The secondary end points were disease control rate (DCR), progression-free survival (PFS), time to treatment failure (TTF), overall survival (OS), duration of response (DoR), and safety of osimertinib. Patients were included in the study on an intention-to-treat basis. RESULTS: Of the 40 eligible patients, 22 were men (55.0%) and the median age was 72 years (range, 39.0-88.0 years). The most common mutations were G719X (20 [50.0%]), S768I (10 [25.0%]), and L861Q (8 [20.0%]). The ORR was 55.0% (90% CI, 40.9%-68.5%) and the DCR was 90.0% (95% CI, 76.3%-97.2%). The median PFS was 9.4 months (95% CI, 3.7-15.2 months) after a median follow-up of 12.7 months (range, 2.7-30.7 months). The median TTF was 9.5 months (95% CI, 5.6-30.3 months), median OS was not reached (NR; 95% CI, 19.3 months to NR), and median DoR was 22.7 months (95% CI, 9.5 months to NR). The ORR for patients with solitary or compound uncommon EGFR mutations was 45.5% (90% CI, 26.9%-65.3%) and 66.7% (90% CI, 43.7%-83.7%), respectively. Median PFS for patients with solitary or compound uncommon EGFR mutations was 5.4 months (95% CI, 3.6-22.7 months) and 9.8 months (95% CI, 5.1 months to NR), respectively. Median OS for patients with solitary or compound uncommon EGFR mutations was 23.0 months (95% CI, 12.3 months to NR) and NR, respectively. Median DoR for patients with solitary or compound uncommon EGFR mutations was 22.7 months (95% CI, 3.6-22.7 months) or NR (95% CI, 5.7 months to NR), respectively. Grade 3 or 4 adverse events were reported by 11 patients (27.5%), and 5 patients (12.5%) developed interstitial lung disease. All adverse events were manageable, and there were no treatment-related deaths. CONCLUSIONS AND RELEVANCE: Osimertinib showed clinical activity with manageable toxic effects among previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations other than exon 20 insertion mutations. The results support the use of osimertinib as a treatment option for this patient population. TRIAL REGISTRATION: Japan Registry of Clinical Trials Identifier: jRCTs071200002.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Okuma Y, Kubota K, Shimokawa M, et al. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2024. PMID: 37991747. doi:10.1001/jamaoncol.2023.5013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。